Valuation: Cipher Pharmaceuticals Inc.

Market Cap 337M 239M 213M 197M 179M 22.66B 342M 2.37B 931M 11.84B 897M 878M 37.86B P/E 2026 *
11.8x
P/E 2027 * 10.9x
Enterprise Value 337M 239M 213M 197M 179M 22.66B 342M 2.37B 931M 11.84B 897M 878M 37.86B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.14x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.75%
1 week-1.11%
Current month-2.20%
1 month-7.42%
3 months-18.70%
6 months-27.80%
Current year-11.35%
1 week 13.25
Extreme 13.25
13.78
1 month 13.25
Extreme 13.25
14.77
Current year 13.25
Extreme 13.25
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 4.3
Extreme 4.3
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 29/07/2019
Director of Finance/CFO - 10/08/2024
Director of Finance/CFO - 15/08/2022
Director TitleAgeSince
Chairman - 12/06/2019
Director/Board Member 78 21/06/2023
Director/Board Member - 21/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A TaxCompany -133,245 0.5243%
9/30/26 A TaxCompany 133,245 0.5243%
9/29/26 A Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-1.11%-10.52%+205.49% 238M
-0.74%+5.47%+54.18%+111.12% 1,120B
-0.80%-4.02%+30.67%+66.18% 616B
-0.43%+0.96%+22.30%+95.03% 504B
+0.24%+5.58%+35.22%+59.40% 367B
-0.67%-0.39%+67.85%+44.27% 360B
-0.40%+3.53%+19.26%+46.55% 288B
-0.37%+3.11%-1.31%+18.23% 258B
-1.04%+2.36%+40.91%+52.32% 234B
-0.88%+2.83%+25.64%+97.20% 194B
Average -0.45%+2.69%+28.42%+79.58% 394.11B
Weighted average by Cap. -0.60%+3.52%+37.54%+76.16%

Financials

2026 *2027 *
Net sales 70.85M 50.29M 44.83M 41.53M 37.76M 4.77B 72.01M 498M 196M 2.49B 189M 185M 7.97B 81.35M 57.74M 51.47M 47.68M 43.35M 5.47B 82.69M 572M 225M 2.86B 217M 212M 9.15B
Net income 27.7M 19.66M 17.53M 16.23M 14.76M 1.86B 28.15M 195M 76.57M 974M 73.77M 72.22M 3.11B 31.76M 22.54M 20.1M 18.62M 16.93M 2.14B 32.28M 223M 87.8M 1.12B 84.58M 82.81M 3.57B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
19/10/26 CA$13.35 +0.75% 2,268
16/10/26 CA$13.25 -2.07% 12,924
15/10/26 CA$13.53 +1.35% 9,101
14/10/26 CA$13.35 -1.11% 11,548
13/10/26 CA$13.50 -1.10% 58,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.25CAD
Average target price
19.45CAD
Spread / Average Target
+46.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.